# To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

> **NCT01222780** · PHASE1 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 22 (actual)

## Conditions studied

- Sarcoma
- Neuroblastoma
- Wilms Tumor
- Leukemia
- Lymphoma
- Brain Tumors

## Interventions

- **DRUG:** Marqibo

## Key facts

- **NCT ID:** NCT01222780
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222780, "To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01222780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*